Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS® (voclosporin)
Adjusts net product revenue guidance to $100-105 million from sales of LUPKYNIS for 2022
Issues preliminary net product revenue guidance for 2023 in the range of $120-140 million from sales of LUPKYNIS
Approximately $400 million of cash, cash equivalents, restricted cash and investments as of October 31, 2022
Conference call to be hosted today at 8:30 a.m. ET
Aurinia will host a conference call and webcast to discuss the quarter ended September 30, 2022 financial results today, Thursday, November 3, 2022 at 8:30 a.m. ET. The audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. In order to participate in the conference call, please dial +1 (877) 407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
https://finance.yahoo.com/news/aurinia-reports-third-quarter-nine-100000805.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.